KOL
September 13, 2021

LARVOL Launches Omni, Its Next Gen KOL and Pharma Tracking Tool

KOL
March 11, 2019

LARVOL Launches Omni, Its Next Gen KOL and Pharma Tracking Tool

Author

Larvol announced the launch of Omni, their newest Medical Communications and Competitive Intelligence tool at the MAPS Annual Conference in New Orleans, LA. The Omni platform, available on both desktop and mobile devices, offers users the ability to track developments related to Key Opinion Leaders, including conferences, social media, and clinical trials in real time.

SAN FRANCISCO–(BUSINESS WIRE) – Larvol, a San Francisco-based pharma SaaS (Software as a Service) company, announced the launch of Omni, their newest Medical Communications and Competitive Intelligence tool at the Medical Affairs Professional Society Annual Conference in New Orleans, LA. The Omni platform, available on both desktop and mobile devices, offers users the ability to track developments related to Key Opinion Leaders, including conferences, social media, and clinical trials in real time.

“We were emboldened by the feedback we received from our customers to develop a dynamic platform that can be widely adopted by Med Comm and Med Affairs teams as well as CI pros who have been relying on our solutions in the pharma industry for more than a decade,” said CEO Dr. Aviva Fridman. “I am excited to get Omni into the hands of customers who will benefit from instant access to their market and KOL data.”

Omni enables users to choose their target KOLs and access their activity instantly via their desktop or mobile device. Features include:

  • Advanced KOL tracking: publications, upcoming events, clinical trials, Sunshine data, and social media relevant to specific KOLs
  • Ability to easily identify critical news, bookmark, and add notes for the KOLs you follow
  • A social experience: like, share, and comment on news items within organizations
  • Additional releases are planned throughout 2019 to enhance Omni functionality including analytics, individual news feeds for pharmaceutical products, diseases, drug pipelines, mechanisms of action, and conference planners

About Larvol:

Larvol provides SaaS solutions that support competitive intelligence, business intelligence, and medical communications departments in the pharmaceutical and biotech industry. Their products include secondary competitive intelligence reports, KOL tracking, and conference planning solutions. Larvol curates pharmaceutical and biotech competitive intelligence using a proven combination of broad therapeutic-area expertise and technological innovation to keep their customers at the forefront of the industry. The Larvol team consists of MDs and PhDs who curate data from over 25,000 sources and distill the most relevant findings into concise reports that provide real-time insights and time-saving analysis.

For more information about Larvol or sales inquiries, please contact us at info@larvol.com. New users can register at www.larvolomni.com.

Contacts
Larvol
info@larvol.com

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.